Login to Your Account

Other News To Note

Wednesday, February 15, 2012
• Gene Signal International SA, of Lausanne, Switzerland, published data in Investigative Ophthalmology & Visual Science demonstrating the activity of aganirsen (GS-101, eye drops) in two models of retinal neovascular disease, wet age-related macular degeneration and ischemic retinopathy. Aganirsen is an antisense oligonucleotide that is expected to complete a Phase III trial in progressive neovascularization in the cornea this year. The data demonstrated the ability of aganirsen to reach and exert activity on the retina.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription